JAMA Network
About The Study: This study of 18,000 residents of long-term care facilities in Israel found that those who had received a third dose (first booster dose) of the Pfizer-BioNTech vaccine had a significantly lower risk for overall SARS-CoV-2 infection, COVID-19 hospitalizations, severe disease and related deaths during the Delta variant surge compared with those who received two doses five months or longer prior to the potential exposure.
Authors: Khitam Muhsen, Ph.D., of Tel Aviv University, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.19940)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
